In-gel fluorescenceshowed dose-dependent labeling of active KLK6, while the mutant wasnot labeled (Figure 3A), and labeling was blocked by preincubation with the broad-spectrumserine hydrolase inhibitor, fluorophosphonate-alkyne (FP-alkyne).We next quantified KLK6 activity in the supernatant of a panel ofpancreatic cancer cells using bABP 17 (IMP-2352) (Figure 3B). The gene discussed is KLK6; the disease is cancer.